New Risk • Aug 12
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 18% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (18% average weekly change). Earnings are forecast to decline by an average of 39% per year for the foreseeable future. Minor Risk Currently unprofitable and not forecast to become profitable next year (₩31b net loss next year). Announcement • Jul 31
OliX Pharmaceuticals, Inc Reports Preclinical Data Demonstrating Greater Visceral Fat Reduction with Olx501a Versus Global Comparator in Obese Non-Human Primates OliX Pharmaceuticals Inc. announced new preclinical data from a head-to-head study in obese non-human primates showing that OLX501A, its ALK7-targeting obesity program, achieved greater visceral fat reduction relative to a globally developed comparator compound. The study was conducted in obese monkeys selected based on predefined criteria for body weight and body fat. OLX501A and the comparator were each administered subcutaneously at 3 mg/kg, with two doses given one month apart. Study endpoints included target gene knockdown, changes in visceral fat volume assessed by MRI, and pharmacodynamic biomarker responses. At Day 49, MRI analysis showed that after adjustment for baseline values and food intake, visceral fat volume in the OLX501A group was reduced by 29.2%. Under the same conditions, the comparator group showed a 10.0% reduction, while visceral fat increased by 11.1% in the control group over the study period. At Day 70, ALK7 mRNA knockdown measured in subcutaneous adipose tissue reached approximately 90% in the OLX501A group, a level generally comparable to that observed with the comparator. Despite generally similar target engagement in subcutaneous fat, OLX501A showed greater reduction in visceral fat. Pharmacodynamic biomarker analyses further supported the differentiated activity profile of OLX501A. Expression of ADRB3, a downstream biomarker associated with lipolysis following ALK7 inhibition, was approximately two-fold higher in the OLX501A group than in the comparator group at Day 28, and this difference was maintained at Day 70. OLX501A is based on OliX’s proprietary OASIS-Adipose platform, an adipose-targeted siRNA technology designed to enable durable gene silencing in fat tissue while limiting exposure in non-target organs. The company has continued to optimize both the chemistry and delivery architecture of the platform to enhance adipose delivery efficiency and sustain pharmacologic activity over time. In earlier mouse studies, OLX501A demonstrated delivery to adipose tissue following subcutaneous administration, durable suppression of target gene expression, and the potential for selective reduction of fat mass while preserving lean mass. Taken together with the new non-human primate data, these findings support the possibility that OLX501A may contribute to improved quality of weight loss by directly modulating fat biology rather than relying primarily on appetite-focused approaches. Across the global obesity treatment landscape, clinical development is increasingly focused not only on weight reduction, but also on broader measures of body composition and metabolic health, including visceral fat, total fat, liver fat, and preservation of lean mass. In parallel, regulatory authorities in major markets have increasingly emphasized sustained reductions in excess body weight, long-term weight maintenance, and broader assessment of metabolic and cardiovascular risk factors in obesity drug development. In this context, data suggesting selective fat reduction and a differentiated body-composition profile may become increasingly relevant in both development strategy and partnering discussions. Announcement • Jul 10
OliX Pharmaceuticals, Inc announced that it has received KRW 10.526832833 billion in funding from Business Opportunities for L'Oréal Development On July 8, 2026, OliX Pharmaceuticals, Inc closed the transaction. On the same day the company changed the expected offering period from July 10, 2026 to July 8, 2026. 
